Email galleryPricing
Get started
Sign InGet started
Email gallery/Geek & Gorgeous/Our 15% Azelaic Acid Serum Guideđź’›
Geek & Gorgeous logoGeek & GorgeousView brand email archive

Our 15% Azelaic Acid Serum Guideđź’›

Migma AI turns this inspiration into an email with your brand’s colors, fonts, and voice.

Create this for my brand
Our 15% Azelaic Acid Serum Guideđź’› email from Geek & Gorgeous screenshot

Make this email yours.

Sign in to create. Your brief comes with you.

Design observations

An educational product guide from Geek & Gorgeous explaining how to use, layer, and pair their new 15% Azelaic Acid AAll Clear serum.

Visual structure

Centered brand logo at top, followed by a headline, introduction text, a detailed infographic pairing guide with product images, CTA buttons, usage instructions, and a social/legal footer.

Email details

Captured
September 29, 2026
Email type
Educational
Industry
Skincare
AI design score
6/10
Language
English
Tone
Friendly
Style
Colorful
Journey stage
Consideration
Primary CTA
ALL CLEAR SERUM
CTA count
2
Animated GIF
No
Dark mode
No

Color palette

Browse related categories

  • Light Mode
  • Colorful
  • Beauty & Personal Care
  • Consideration
  • Newsletter Subscribers
  • Newsletter
How does Migma learn my brand?

Import your website in Migma, then review your logo, colors, fonts, and brand voice. AI uses those settings and your brief to create an editable email. See how brand setup works.

Was this example made with Migma AI?

This is an archived brand email, shown for inspiration. The archive does not establish how it was made. Remixing starts a new email for your own brand.

What can I download or export?

Download preview saves an image of this example. Export HTML downloads its original source on a paid plan, subject to daily limits. You can also edit and export the new email you create in Migma. View plans.

Archived for design inspiration. Original email and brand assets belong to their respective owners. Design observations describe the creative; they are not campaign results.

Solutions

  • Marketers
  • Designers
  • Developers
  • Enterprise

Resources

  • Countdowns
    New
  • Email gallery
  • Pricing
  • Docs
  • Blog

Company

  • About Us
  • Brand guidelines
  • Brand kit
  • Careers
  • Support
  • FAQ

Legal

  • Privacy Policy
  • Terms & Conditions
  • Do not sell or share my personal information
  • Copyright Notice & Takedown
  • Data Processing Agreement
  • Acceptable Use

Socials

  • X / Twitter
  • Discord
  • YouTube
  • LinkedIn
MigmaAI
© 2026 MigmaAI, Inc. All rights reserved.
Backed byEWOR Logo DarkEWOR Logo Light
Built with ❤️ in Stockholm & Barcelona

More emails like this

Explore other emails with shared design, campaign, or industry tags.

September Property Special: Get into the market sooner email from Pepper Money
PMPepper Money

September Property Special: Get into the market sooner

We’re obsessed: behold Ilia’s new eyeliner email from Naturisimo
NNaturisimo

We’re obsessed: behold Ilia’s new eyeliner

South Korea’s chip giants race for the U.S. AI boom email from Rest of World
RORest of World

South Korea’s chip giants race for the U.S. AI boom

Watson Realty is paying for its agents' security. Here's why email from Real Estate Connect
REReal Estate Connect

Watson Realty is paying for its agents' security. Here's why

67 AI startups fighting rogue agents email from PitchBook
PitchBook logoPitchBook

67 AI startups fighting rogue agents

A serious AI product 🧪, AI agents like new hires 🧑‍💼, the cost of delegating to AI 🧠 email from TLDR Cybersecurity
TLDR Cybersecurity logoTLDR Cybersecurity

A serious AI product 🧪, AI agents like new hires 🧑‍💼, the cost of delegating to AI 🧠

Live now: Inside a 7-Figure CPA Offer with Orbio email from RedTrack
RedTrack logoRedTrack

Live now: Inside a 7-Figure CPA Offer with Orbio

Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis email from Novo Nordisk
Novo Nordisk logoNovo Nordisk

Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis